Skip to main content
Premium Trial:

Request an Annual Quote

Acuamark Diagnostics Raises $11.3M to Support Cancer Detection Test Development

NEW YORK – Cancer early detection firm Acuamark Diagnostics said Wednesday that it has closed an $11.3 million Series A financing round, led by the office of Claudio Del Vecchio and the Del Vecchio Family Foundation and joined by Bruker as a new investor.

Del Vecchio also joined Acuamark's board of directors.

Acuamark, formerly iCareDx, is developing ultra-sensitive, automatable blood tests for accurate, cost-effective early cancer detection and said that it will use the Series A proceeds to scale its sample collections.

The New York company has described its platform as a proprietary PCR-based multiplexing technology that can detect a variety of cancer biomarkers such as mutations and gene expression signatures.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.